FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an agent possessing normothymic activity and containing 0.65-1.95 wt % of potassium chloride, 0.007-0.021 wt % of magnesium sulphate, 0.0028-0.0084 wt % of zinc sulphate, 0.00065-0.00195 wt % of rubidium chloride and water.
EFFECT: invention provides normalisation of the CNS function ensured by normothymic activity.
2 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
NOOTROPIC AGENT | 2012 |
|
RU2493856C1 |
MOOD STABILISING AGENT | 2010 |
|
RU2416421C1 |
HERBAL PREPARATION POSSESSING MOOD STABILIZING ACTION | 2019 |
|
RU2717963C1 |
PSYCHOSTIMULANT AGENT | 2010 |
|
RU2438677C1 |
USE OF N,N"-SUBSTITUTED 3,7-DIAZABICYCLO[3_3_1]NONANES DERIVATIVES FOR DEPRESSION THERAPY | 2019 |
|
RU2726313C1 |
3,6,9-TRIAZATRICYCLOTETRADECANE DERIVATIVE AND USE THEREOF FOR TREATING DEPRESSION | 2019 |
|
RU2700595C1 |
BIOLOGICALLY ACTIVE FOOD ADDITIVE | 2013 |
|
RU2552006C1 |
METHOD FOR PROLONGING BIOLOGICAL ACTIVITY OF LITHIUM SALTS | 1992 |
|
RU2050852C1 |
NOOTROPIC AGENT | 2011 |
|
RU2475250C1 |
AGENT SHOWING ANXIOLYTIC ACTION | 2011 |
|
RU2464990C1 |
Authors
Dates
2012-12-27—Published
2011-05-16—Filed